Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7546 to 7560 of 8314 results

  1. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    In development Reference number: GID-TA10895 Expected publication date:  29 October 2026

  2. Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]

    In development Reference number: GID-TA11367 Expected publication date: TBC

  3. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development Reference number: GID-TA11117 Expected publication date: TBC

  4. Botulinum toxin type A for preventing episodic migraine [ID6450]

    In development Reference number: GID-TA11505 Expected publication date: TBC

  5. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued Reference number: GID-IP1041

  6. Extra corporeal membrane oxygenation for acute heart failure in children

    Discontinued Reference number: GID-IP1153

  7. Intravaginal sling for stress urinary incontinence

    Discontinued Reference number: GID-IP267

  8. High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

    Discontinued Reference number: GID-IPG10142

  9. PredictSURE IBD and IBDX to guide treatment of Crohn's disease (DG45)

    We have moved Diagnostics guidance 45 to become HealthTech guidance 610. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  10. EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (DG46)

    We have moved Diagnostics guidance 46 to become HealthTech guidance 611. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  11. Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) (DG47)

    We have moved Diagnostics guidance 47 to become HealthTech guidance 619. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  12. FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (DG48)

    We have moved Diagnostics guidance 48 to become HealthTech guidance 682. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  13. PLGF-based testing to help diagnose suspected preterm pre-eclampsia (DG49)

    We have moved Diagnostics guidance 49 to become HealthTech guidance 630. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  14. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)

    We have moved Diagnostics guidance 5 to become HealthTech guidance 291. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.